NCT05736341View on ClinicalTrials.gov

Comparison of Remimazolam and Midazolam for Preventing Intraoperative Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 17, 2023

Primary Completion Date

May 17, 2023

Study Completion Date

January 6, 2024

Conditions
PregnancyCesarean SectionSpinal Anesthesia
Interventions
DRUG

Remimazolam besylate

After delivery, patients in this group receives 5mg of remimazolam to induce sedation during the remaining procedures of Cesarean section.

DRUG

Midazolam

After delivery, patients in this group receives 2mg of midazolam to induce sedation during the remaining procedures of Cesarean section.

Trial Locations (1)

Unknown

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT05736341 - Comparison of Remimazolam and Midazolam for Preventing Intraoperative Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia | Biotech Hunter | Biotech Hunter